Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL780217 | 0.89 | SLC18A3 (0.43) | SLC18A3SIGMAR1GAAMAPTDRD2 | |
| SCHEMBL60704 | 0.87 | SLC18A3 (0.56) | SLC18A3SIGMAR1GAAMAPTAKR1C3 | |
| SCHEMBL10405997 | 0.87 | SLC18A3 (0.43) | SLC18A3SIGMAR1DRD2TRPA1CYP2D6 | |
| SCHEMBL9517294 | 0.82 | KDM1A (0.49) | — | |
| SCHEMBL9517286 | 0.82 | KDM1A (0.49) | — | |
| SCHEMBL2013478 | 0.81 | SLC18A3 (0.48) | SLC18A3SIGMAR1GAAMAPTAKR1C3 | |
| SCHEMBL35975 | 0.81 | SLC18A3 (0.45) | SLC18A3SIGMAR1GAAMAPTAKR1C3 | |
| SCHEMBL3001780 | 0.81 | SLC18A3 (0.45) | SLC18A3SIGMAR1GAAMAPTAKR1C3 | |
| SCHEMBL29557767 | 0.81 | SLC18A3 (0.45) | SLC18A3SIGMAR1GAAMAPTAKR1C3 | |
| SCHEMBL16048164 | 0.79 | SLC18A3 (0.48) | SLC18A3SIGMAR1TRPA1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116802179-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-09-22 | — | — | CN | claimed |
| US-20230159522-A1 | BCL-2 INHIBITOR | BEONE MEDICINES I GMBH (CH) | 2023-05-25 | — | — | US | claimed |
| EP-4136084-A1 | BCL-2 INHIBITOR | BeiGene, Ltd. (KY) | 2023-02-22 | — | — | EP | claimed |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2021-12-02 | — | — | US | claimed |
| WO-2021208963-A1 | BCL-2 INHIBITOR | BEIGENE, LTD. (KY) | 2021-10-21 | — | — | WO | claimed |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A ST CO., LTD. (KR) | 2019-10-17 | — | — | US | claimed |
| EP-3523292-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | Dong-A Socio Holdings Co., Ltd. (KR) | 2019-08-14 | — | — | EP | claimed |
| WO-2018071343-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2018-04-19 | — | — | WO | claimed |
| CN-103635458-B | Trpv1 antagonists | 艾伯维公司 | 2016-10-19 | — | — | CN | claimed |
| US-7304086-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2007-12-04 | — | — | US | claimed |
| US-11970495-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-30 | — | — | US | disclosed |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | KIND PHARMACEUTICAL (CN) | 2024-04-02 | — | — | US | disclosed |
| CN-116969937-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116969936-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116802179-A | BCL-2 inhibitors | 百济神州有限公司 | 2023-09-22 | — | — | CN | disclosed |
| EP-0913392-A1 | ETHYLENE DERIVATIVES AND PEST CONTROLLING AGENTS | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1999-05-06 | — | — | EP | disclosed |
| CN-1043232-C | Catalyst composition and use of same for oligomerizing or polymerizing olefins | SHELL INT RESEARCH (NL) | 1999-05-05 | — | — | CN | disclosed |
| US-4871864-A | Carbamoyloxythiophene fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 1989-10-03 | — | — | US | disclosed |
| US-4839381-A | FUNGICIDES, PESTICIDES; RICE PLANTS | BAYER AKTIENGESELLSCHAFT (DE) | 1989-06-13 | — | — | US | disclosed |
| US-4757085-A | Pharmaceuticals | BAYER AKTIENGESELLSCHAFT (DE) | 1988-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11970495-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | SLC18A3 410/4885SIGMAR1 1467/4885GAA 2946/4885 |
| US-20190315716-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB4 | SLC18A3 3712/4885SIGMAR1 1204/4885GAA 1303/4885 |
| US-20210371398-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS | MERTK, RET, ERBB2 | SLC18A3 3210/4885SIGMAR1 924/4885GAA 1225/4885 |
| US-20230159522-A1 | BCL-2 INHIBITOR | BCL2, BCL2A1, BCL2L1 | SLC18A3 4723/4885SIGMAR1 4650/4885GAA 1597/4885 |
| US-11945817-B2 | Indolizine derivatives and their application in medicine | INMT, IDO1, IDO2 | SLC18A3 410/4885SIGMAR1 1467/4885GAA 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.